Caribou Biosciences to Participate in Citi’s 16Th Annual BioPharma Virtual Conference
September 01 2021 - 8:00AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today
that Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer, will participate in a panel discussion entitled
“Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the
State of Play in Cell Therapy” on Thursday, September 9, 2021 at
10:40 am ET. The panel is being hosted at Citi’s 16Th Annual
BioPharma Virtual Conference.
A live and archived webcast of the discussion will be accessible
on the Events page of the Investors section on Caribou’s website at
www.cariboubio.com for 30 days following the event.
About Caribou Biosciences, Inc.Caribou is a
clinical-stage CRISPR genome-editing biopharmaceutical company
dedicated to transforming the lives of patients with devastating
diseases by applying the company’s proprietary chRDNA technology
toward the development of next-generation, genome-edited cell
therapies. The company is developing a pipeline of genome-edited,
off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of
both hematologic malignancies and solid tumors against cell surface
targets for which autologous CAR-T cell therapeutics have
previously demonstrated clinical proof of concept, as well as
additional emerging targets.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc. Media Contact: |
Caribou Biosciences, Inc. Investor Relations
Contact: |
Greg Kelley |
Elizabeth Wolffe, Ph.D. and
Sylvia Wheeler |
Ogilvy |
Wheelhouse LSA |
gregory.kelley@ogilvy.com |
lwolffe@wheelhouselsa.com |
617-461-4023 |
swheeler@wheelhouselsa.com |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024